Vertex Pharmaceuticals Incorpor with ticker code (VRTX) have now 20 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 279 and 183 with a mean TP of 223.5. With the stocks previous close at 194.02 this now indicates there is a potential upside of 15.2%. There is a 50 day moving average of 175.9 and the 200 day MA is 175.41. The market cap for the company is $49,919m. You can visit the company’s website by visiting: http://www.vrtx.com
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics, as well as a strategic collaboration with Ribometrix, Inc. to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.